SAN

73.36

-1.45%↓

SRT3

224.45

-1.64%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.3

+2.15%↑

SAN

73.36

-1.45%↓

SRT3

224.45

-1.64%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.3

+2.15%↑

SAN

73.36

-1.45%↓

SRT3

224.45

-1.64%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.3

+2.15%↑

SAN

73.36

-1.45%↓

SRT3

224.45

-1.64%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.3

+2.15%↑

SAN

73.36

-1.45%↓

SRT3

224.45

-1.64%↓

ORNBV.FI

68.5

+3.4%↑

PHMA

95.6

-1.49%↓

DRW3

90.3

+2.15%↑

Home・Listă Acțiuni・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Deschisă

SectorSănătate

79.55 1.66

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

79.55

Maxim

79.8

Indicatori cheie
By Trading Economics
Venit	-33M 43M
Vânzări	7.9M 218M
P/E Medie Sector	33.502 49.8
EPS	0.834
Marjă de profit	19.539
Angajați	1,950
EBITDA	-21M 63M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+8.57% upside

Dividende
By Dow Jones
Următoarele câștiguri	23 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	84M 4.1B
Deschiderea anterioară	77.89
Închiderea anterioară	79.55

Sentimentul știrilor

By Acuity

100%

331 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

51.1 / N/A Suport & Rezistență

Laboratorios Farmaceuticos Rovi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 mai 2026, 23:41 UTC

Câștiguri

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

6 mai 2026, 21:40 UTC

Câștiguri

Nutrien Logs Higher Profit, Sales Growth in 1Q

6 mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

6 mai 2026, 23:34 UTC

Market Talk

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

6 mai 2026, 23:13 UTC

Câștiguri

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

6 mai 2026, 23:13 UTC

Câștiguri

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

6 mai 2026, 23:12 UTC

Câștiguri

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

6 mai 2026, 23:11 UTC

Câștiguri

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

6 mai 2026, 23:11 UTC

Câștiguri

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

6 mai 2026, 23:07 UTC

Câștiguri

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

6 mai 2026, 23:06 UTC

Câștiguri

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

6 mai 2026, 23:06 UTC

Câștiguri

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

6 mai 2026, 23:05 UTC

Câștiguri

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

6 mai 2026, 23:04 UTC

Câștiguri

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

6 mai 2026, 22:50 UTC

Câștiguri

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

6 mai 2026, 22:25 UTC

Market Talk

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

6 mai 2026, 22:11 UTC

Câștiguri

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

6 mai 2026, 22:11 UTC

Câștiguri

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

6 mai 2026, 22:05 UTC

Market Talk

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

6 mai 2026, 21:58 UTC

Câștiguri

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:47 UTC

Market Talk

Câștiguri

Costco Posts 13% Sales Growth in April -- Market Talk

6 mai 2026, 21:46 UTC

Câștiguri

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

6 mai 2026, 21:40 UTC

Câștiguri

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

6 mai 2026, 21:35 UTC

Market Talk

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

6 mai 2026, 21:32 UTC

Acțiuni populare

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

6 mai 2026, 21:29 UTC

Câștiguri

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Comparație

Modificare preț

Laboratorios Farmaceuticos Rovi SA Așteptări

Obiectiv de preț

By TipRanks

8.57% sus

Prognoză pe 12 luni

Medie 86.75 EUR 8.57%

Maxim 90 EUR

Minim 83.5 EUR

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLaboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Laboratorios Farmaceuticos Rovi SA - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

51.1 / N/ASuport & Rezistență

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

331 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.